$51.7 Million is the total value of ABG-WTT Global Life Science Capital Partners GP Ltd's 2 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVL | MEDAVAIL HOLDINGS INC | $47,603,000 | -12.5% | 3,885,951 | 0.0% | 92.00% | +55.0% | |
| LUNG | Sell | PULMONX CORP | $4,140,000 | -88.9% | 93,831 | -88.5% | 8.00% | -80.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 12 | Q3 2023 | 92.0% |
| PULMONX CORP | 12 | Q3 2023 | 49.0% |
| RAPID MICRO BIOSYSTEMS INC | 7 | Q3 2023 | 57.2% |
| RAYZEBIO INC | 1 | Q3 2023 | 83.0% |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.